Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of inhaled formoterol vs standard COPD treatment in Japanese COPD patients
jRCT2080221001Phase 3
- Sponsor
- AstraZeneca
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca.
02
Drugs
formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080221001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221001.